Conclusion
Treatment of SGAH-unresponsive CSU subjects, with benralizumab 30mg subcutaneously monthly for 3 successive months, versus a placebo dose, significantly improved disease severity and QoL as measured by UAS7 and CU-QoL total score, respectively. These observations support the use of benralizumab for treatment of SGAH unresponsive CSU and provide evidence for a pathogenic role for infiltrating eosinophils. These data provide justification for a double-blind, placebo-controlled multicenter study in a large patient population currently underway.